Consistent with previous literature, the investigators postulate that a leucine-restricted diet is safe and well-tolerated in gastric cancer patients receiving neoadjuvant chemo-immunotherapy. Furthermore, the investigators propose that this dietary regimen promotes the activation of immune cells within the tumor microenvironment (TME). When combined with neoadjuvant chemo-immunotherapy, it demonstrates synergistic anti-tumor efficacy, thereby improving patient prognosis.
Pathological Confirmation: Histologically confirmed locally advanced gastric cancer.
Demographics: Aged 18 to 70 years, inclusive, regardless of gender.
Dietary Capability: Capable of oral intake or receiving a liquid diet via nasogastric tube.
Consent: Willing to participate in the study and have signed the Written Informed Consent Form (ICF).
Cognitive or Psychiatric Impairment: Cognitive dysfunction or psychiatric disorders severe enough to prevent the patient from understanding the study content or providing informed consent.
Diabetes Mellitus: Diagnosis of Type 1 or Type 2 diabetes mellitus.
Gastrointestinal Conditions: Presence of severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralytic or mechanical intestinal obstruction, or active gastrointestinal bleeding.
Allergy/Hypersensitivity: Known hypersensitivity or allergy to any of the main components of the leucine-deficient nutritional powder.